（文章来源：每日经济新闻） 每经AI快讯，10月8日，港股和誉-B(02256.HK)早盘涨超8%，截至发稿，涨8.2%，报19.4港元，成交额 5846.51万港元。 ...

同比增长14.8%！——这是日前公布的1—8月份石家庄固定资产投资增速，比去年同期提高了5.1个百分 点。 经济发展的"晴雨表"上，固定资产投资的动向总能折射出区域发展的底气与潜力。14.8%的增速，分别 高于全国、全省14.3和8.6个百分点。 稳快增长从何而来？ 今年以来，石家庄牢牢把握高质量发展首要任务，聚焦年度投资目标任务，系统谋划、提前储备、加快 前期、优化服务，全力以赴推动投资项目建设。一个个规模大、质量高、带动力强的项目加速推进，一 批批高端化、智能化、绿色化产业集聚发展，迸发出助推全市经济社会高质量发展的"新引擎"和"硬支 撑"。 大项目支撑 发展后劲足 初秋的石家庄，处处涌动着建设热潮。 步入泰威航科全动模拟器生产基地项目的建设现场，只见一号检测楼已封顶，主体生产车间、仓库正在 进行钢结构安装……这个总投资30亿元的省重点项目，预计明年3月竣工投产，可每年生产约10台D级 全动模拟器，年产值超10亿元。 塔吊巨臂挥舞，运输车辆穿梭，焊接火花四溅……走进河北高速集团电子科技产业园项目现场，热火朝 天的繁忙景象扑面而来。项目布局了研发孵化楼、独立厂房、中试车间等49栋多元建筑，积极服务京津 冀协 ...

Core Insights - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and announced four abstract presentations at the upcoming AASLD The Liver Meeting® 2025 [1][6] Presentation Details - The first abstract compares digital images versus glass slides for histopathological evaluation of liver biopsy samples in the NATiV3 study, scheduled for presentation on November 8, 2025 [2][3] - The second abstract discusses continuous digital pathology scoring revealing fibrosis reversal and therapeutic benefits of lanifibranor, with a presentation date of November 9, 2025 [2] - The third abstract highlights high-resolution digital pathology demonstrating antifibrotic and anti-inflammatory effects of lanifibranor in TAA-induced cirrhotic rodent models, also on November 9, 2025 [2] - The fourth abstract combines digital pathology and biomarkers to quantify fibrosis and treatment response to lanifibranor in a TAA-induced cirrhosis model, presented on November 9, 2025 [2] About Lanifibranor - Lanifibranor is Inventiva's lead product candidate, an orally available small molecule that activates all three PPAR isoforms, inducing anti-fibrotic and anti-inflammatory effects [5][6] - It is the only pan-PPAR agonist in clinical development for MASH, with the FDA granting Breakthrough Therapy and Fast Track designations [5] Company Overview - Inventiva is a public company listed on Euronext Paris and NASDAQ, focusing on the research and development of oral small molecule therapies for MASH [6][7]

Summary of Ionis Pharmaceuticals 2025 Investor Day Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **Event**: 2025 Investor Day held on October 07, 2025 - **Objective**: To update stakeholders on the progress in transforming the lives of patients with severe unmet medical needs through innovative medicines and technology [1][2] Key Industry Insights - **Focus Areas**: Neurology and cardiometabolic diseases, both of which have high unmet medical needs [16] - **Pipeline**: Ionis has a robust pipeline with 10 medicines in late-stage development, aiming for continuous Phase III data readouts [14][18] Core Points and Arguments - **Commercial Strategy**: Ionis has transitioned to a fully integrated biotechnology company with its first two independent commercial launches, aiming for positive cash flow and growing revenue [6][10][20] - **Recent Achievements**: - Six positive Phase III data readouts in the last two years, leading to four approved medicines [14] - Launch of Trangolza for Familial Chylomicronemia Syndrome (FCS) and Donzera for hereditary angioedema [22][26] - **Future Launches**: Anticipation of three more FDA-approved medicines in the upcoming year, including olazarsen for severe hypertriglyceridemia [20][21] Financial Strategy - **Path to Cash Flow**: Ionis is focused on achieving positive cash flow in the near term through its independent launches and pipeline advancements [6][39] - **Investment in Research**: Successful launches will allow reinvestment into research and development, enhancing the pipeline further [38] Pipeline Highlights - **Neurology**: - SPINRAZA and CALSADI are breakthrough treatments for spinal muscular atrophy and ALS, respectively [16] - Eleven medicines in the neurology pipeline, including treatments for dementia and rare pediatric neurological diseases [17] - **Cardiometabolic**: - Olazarsen is positioned for FDA approval next year, targeting severe hypertriglyceridemia, with significant clinical data showing a 72% mean placebo-adjusted reduction in triglycerides [24][25] - Other candidates include pelicarcin for Lp-driven cardiovascular disease and eplontirsen for ATTR cardiomyopathy [17][38] Clinical Insights - **Triglyceride Disorders**: - FCS is a severe genetic disorder with high triglyceride levels leading to acute pancreatitis; Ionis's Trangolza is the first FDA-approved treatment for this condition [22][61] - Olazarsen has shown an 85% reduction in acute pancreatitis events, marking a significant breakthrough in treatment [25][66] - **Patient Impact**: Positive feedback from patients and healthcare providers regarding the efficacy and tolerability of new treatments [23][28] Research and Development - **Innovative Technologies**: Ionis is expanding its drug discovery capabilities, focusing on new platforms and targeted delivery systems to enhance treatment efficacy [40][41] - **Future Directions**: Plans to initiate new clinical studies in various therapeutic areas, including neuromuscular diseases and cardiac conditions [43][44] Conclusion - **Outlook**: Ionis Pharmaceuticals is well-positioned for future growth with a strong pipeline, innovative treatments, and a clear path to financial self-sufficiency, aiming to deliver transformative medicines for patients with severe diseases [45][46]

Major Events - Huiying Holdings (00821) plans to establish a joint venture to provide training, professional consulting services, and high-end conference business in the RWA category [1] - MIRXES-B (02629) intends to set up a joint venture for research, development, and commercialization of early cancer detection and other nucleic acid-based tests in Malaysia [1] - Kintor Pharmaceutical-B (02171) will present updates on the research results of CT0596 at the 2025 ASH annual meeting [1] - Energy & Energy Global (01142) has had its mining license revoked by a Russian subsidiary and plans to appeal further [1] Operating Performance - C&D International Group (01908) reported a cumulative contract sales amount of approximately 71.03 billion yuan for the first nine months, representing a year-on-year increase of about 7.5% [1] - Sa Sa International (00178) recorded a total revenue of 1.031 billion HKD for the second quarter, an annual increase of 8.4% [1] Buybacks/Reductions - Hang Seng Bank (00011) repurchased 200,000 shares for 23.9836 million HKD on October 6 [1] - Tencent Holdings (00700) repurchased 815,000 shares for 550.3 million HKD on October 6 [1] - Mengniu Dairy (02319) repurchased 1 million shares for 14.4099 million HKD on October 6 [1] - HSBC Holdings (00005) repurchased 1.49 million shares for 163 million HKD on October 3 [1]

Group 1 - The Nobel Prize in Physiology or Medicine for 2025 was awarded to scientists Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their contributions to peripheral immune tolerance research, specifically the discovery of regulatory T cells [1][3] - The prize amount is 11 million Swedish Krona, approximately 8.32 million RMB, which will be equally divided among the three winners [1] - Their discoveries are expected to lead to new directions in the treatment of autoimmune diseases and the improvement of cancer immunotherapy [1][5] Group 2 - Domestic companies are actively engaging in the field of regulatory T cell therapy, with collaborations and clinical projects underway [5][6] - On May 29, 2025, Haier International Cell Bank and Cellxin Biotech initiated a clinical application project focused on regulatory T cell therapy for conditions like Amyotrophic Lateral Sclerosis (ALS) [5] - Cellxin Biotech announced that its clinical research project on the safety and tolerability of regulatory T cell therapy for neurodegenerative diseases received ethical approval from Zhengzhou University First Affiliated Hospital [5] - He Yuan Biological signed a strategic cooperation agreement with Cellxin Biotech to provide clinical trial sample preparation and testing services for Treg cell therapy [5] - Binoji Biotech, established in November 2021, focuses on innovative T cell therapies for solid tumors and autoimmune diseases, with its product BEN-301 aimed at treating autoimmune diseases currently in preclinical development [6]

Oculis Holding Update Summary Company Overview - **Company**: Oculis Holding AG - **Ticker**: NasdaqGM: OCS - **Industry**: Biopharmaceuticals focusing on neuro-ophthalmology - **Market Potential**: Over $25 billion in neuro-ophthalmology with specific indications for OCS-05 targeting acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION) [4][12][14] Key Developments - **FDA Interaction**: Successful meeting with the U.S. FDA allowing OCS-05 to advance into the registration phase for AON and NAION [5][6] - **Registration Trials**: - **Pioneer 1**: Planned to start in Q4 2025 for AON - **Pioneer 2**: Planned to start in the first half of 2026 for AON - **Pioneer 3**: Planned to start in mid-2026 for NAION [6][7][15] Clinical Trial Design - **Pioneer Trials**: - Pioneer 1 and 2 will mirror the successful Phase 2 Acuity trial with the same dose and patient population [6][9] - Primary endpoint: Change from baseline in Low Contrast Visual Acuity (LCVA) at month three [10][12] - Secondary endpoints include the proportion of 15-letter gainers at month three and change from baseline in LCVA at month six [10][12] Market Opportunity - **Acute Optic Neuritis (AON)**: - Estimated 30,000 cases per year in the U.S. - Potential market size of over $3 billion with treatment costs between $100,000 to $400,000 per year [12][13] - **Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)**: - Estimated 30,000 to 35,000 cases per year in the U.S. - Potential market size of over $4 billion [14][15] Financial Position - **Balance Sheet**: Strong with no debt and cash runway extending to the end of 2027 without utilizing loan facilities [5] Strategic Focus - **Pipeline**: Multiple pivotal milestones focusing on significant unmet medical needs in neuro-ophthalmology [15][16] - **Future Plans**: - Launching Predict, a Phase 3 trial in genotype-based development for dry eye [15] - Aiming to leverage data from AON trials for potential MS relapse indications [9][15] Regulatory and Clinical Insights - **Regulatory Pathway**: Full alignment with FDA on trial designs and IND submissions for both AON and NAION [5][6] - **Patient Population**: Trials will include both MS and non-MS patients, with a focus on all-comers for AON [9][12] - **Treatment Window**: Treatment should ideally start within 12 days of symptom onset, with an average of 9.5 days observed in previous studies [61] Community Engagement - **Feedback from Neuro-Ophthalmologists**: Positive reception and engagement from the medical community regarding OCS-05, with plans for strong presence at upcoming medical congresses [73][74] Conclusion - Oculis is positioned to be a leader in neuro-ophthalmology with a robust pipeline and significant market opportunities in AON and NAION, aiming to address critical unmet medical needs while maintaining a strong financial foundation [15][16][60]

今天分享的是：2025年跨国公司在中国：投资未来共赢发展再起航报告 报告共计：80页 跨国公司深耕中国：共赢发展开启新征程，多重机遇勾勒投资新图景 在经济全球化深度调整的当下，中国凭借稳定的发展环境、持续优化的营商生态以及广阔的市场空间，依然是跨国公司全球布 局的重要选择。商务部国际贸易经济合作研究院2025年6月发布的《跨国公司在中国：投资未来共赢发展再起航》报告，系统梳 理了跨国公司与中国经济共生共荣的历程，展现了全球投资变局下中国市场的独特价值，也为跨国公司在华发展指明了新方 向。 回顾过往，跨国公司已深度融入中国经济发展脉络，成为推动中国开放型经济水平提升、现代化产业体系构建的重要力量。 2024年，中国新设外商投资企业5.9万家，同比增长9.9%，实际使用外资1162亿美元，截至2024年底，外商累计在华设立企业超 123.9万家，累计实际使用外资达20.6万亿元人民币。即便受国际形势影响，中国吸收外资规模虽有波动，但仍稳居发展中国家 前列。从投资结构看，高技术领域成为热点，2024年医疗仪器设备及仪器仪表制造业、专业技术服务业、计算机及办公设备制 造业实际使用外资分别增长98.7%、40.8%和2 ...

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (科济药业-B) has seen a significant increase in stock price, attributed to the upcoming presentation of clinical data for CT0596 at the 67th American Society of Hematology (ASH) annual meeting and the recent approval of its CAR-T drug for inclusion in insurance directories [1]. Group 1: Stock Performance - Kintor Pharmaceutical's stock price rose over 7% during trading, with a current increase of 5.70%, reaching HKD 19.85 [1]. - The trading volume amounted to HKD 13.3487 million [1]. Group 2: Clinical Data Presentation - The company announced that it will present clinical data for its drug CT0596 at the ASH annual meeting [1]. Group 3: Regulatory Developments - On September 20, the National Healthcare Security Administration announced the completion of expert review work for the first version of the commercial insurance innovative drug directory [1]. - Kintor's CAR-T drug, Sai Ke Ze, along with four other CAR-T drugs, successfully passed the expert review, indicating a potential inclusion in this year's basic medical insurance directory and commercial insurance innovative drug directory [1].

Group 1 - Kintor Pharmaceutical (科济药业-B) shares rose over 7%, currently up 6.39% at HKD 19.98, with a trading volume of HKD 10.51 million [1] - The company announced it will present clinical data for CT0596 at the 67th American Society of Hematology (ASH) annual meeting [1] - On September 20, the National Healthcare Security Administration announced the completion of expert review for the first version of the commercial insurance innovative drug catalog, with Kintor's CAR-T drug, Sai Ke Ze, among five CAR-T drugs that passed the review, potentially entering this year's basic medical insurance and commercial insurance innovative drug catalog [1]